The Gustave Roussy Institute and Merus collaborate to jointly develop bispecific antibodies for oncology applications.
J&J acknowledged that the efficacy percentages varied depending where the vaccine was administered, with a low of 57% in South Africa, where a variant strain of SARS-CoV-2 from the from the B.1.351 lineage accounted nearly all cases 28 days post-vaccination. Percentages stood at 66% in Latin America and 72% in the U.S.
Start of Phase I trials with topical IL-1 antagonist against dry eye syndrome is expected this year.
MAB Discovery has added Sanofi to its list of partners through a monoclonal antibody research and license agreement announced today.
Firms aim to bolster ProteoTech's alpha-synuclein program.
AstraZeneca has agreed to pay potentially more than $6.9 billion to co-develop Daiichi Sankyo’s Trastuzumab deruxtecan—just months before the first application to market the...
Scientists at the University of Pittsburgh School of Medicine announced a positive step forward in the development of a potential vaccine against SARS-CoV-2. The vaccine, which can be delivered through a fingertip-sized patch that does not require refrigeration, produces SARS-CoV-2 specific antibodies in mice at quantities thought to be sufficient for neutralizing the virus. The authors hope to start a Phase I human clinical trial within a few months.
Alliance will provide clients with full suite of services to bring biosilimilars to market.
Researchers from the University of Sheffield say they have identified a new potential treatment pathway for cardiovascular disease.